Japanese encephalitis is a virus that is spread by mosquitoes. It can cause swelling of the brain. It also affects the central nervous system. Japanese encephalitis can cause severe complications, like long-term neurological disability and death.
People get Japanese encephalitis when they are bitten by a mosquito infected with the virus. Japanese encephalitis is a common cause of viral encephalitis in Asia. It can be prevented by vaccines.
Many people with the infection may have no symptoms. If symptoms develop, they can include:
Symptoms of Japanese encephalitis usually appear 5-15 days after the bite from an infected mosquito.
There is no specific treatment for this condition. Care for people with the disease is aimed at easing symptoms.
The vaccine is made from an inactive form of the virus. It is called Ixiaro and is for people aged 17 years and older.
IMOJEV is a vaccine made from live virus that is weakened. It is not available in the United States.
The vaccine is recommended for people who are traveling to Asia and are:
Lab workers who may be exposed to Japanese encephalitis should also get the vaccine.
There is no vaccine available in the United States for young children. Children under age 17 who will be traveling to a high-risk area can visit a travel clinic abroad or enroll in a clinical trial. Visit the Centers for Disease Control and Prevention (CDC) website for more information.
The Japanese encephalitis vaccine is given in a series of 2 shots within 28 days. The last dose needs to be given within 1 week of traveling to Asia.
Like any vaccine, the Japanese encephalitis vaccine can cause problems, such as severe allergic reactions. The risk of serious harm or death is extremely small.
The most commonly reported problems from the Japanese encephalitis vaccine are mild and include:
Talk to your doctor before getting the vaccine if you:
The vaccine is not 100% effective at preventing the disease. It is important to protect yourself from mosquito bites. The CDC recommends:
WHERE CAN I GET MORE INFORMATION?
Centers for Disease Control and Prevention
Immunization Action Coalition
Clinical trials sites in the United States for Ixiaro in children under 17. Centers for Disease Control and Prevention website. Available at http://www.cdc.gov/ncidod/dvbid/jencephalitis/resources/UpdtJEVaccChildren_Web_Table1.pdf. Accessed November 19, 2013.
Dubischar-Kastner K, Kaltenboeck A, et al. Safety analysis of a Vero cell culture-derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. Vaccine. 2010;28(39):6463-6469.
Fischer M, Lindsey N, et al; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-1):1-27.
Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011;10(3):355-364.
Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis. 2010;50(8):1155-1164.
Japanese encephalitis. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated May 22, 2013. Accessed November 19, 2013.
Lehtinen VA, Huhtamo E, et al. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol. 2008;43(1):93-95.
Wilder-Smith A, Halstead SB. Japanese encephalitis: update on vaccines and vaccine recommendations. Curr Opin Infect Dis. 2010;23(5):426-431.
Last reviewed December 2014 by David L. Horn, MD, FACP
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2012 EBSCO Publishing All rights reserved.
What can we help you find?close ×